Compare PARR & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PARR | ARDX |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2000 | 2014 |
| Metric | PARR | ARDX |
|---|---|---|
| Price | $40.86 | $6.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $46.20 | $14.67 |
| AVG Volume (30 Days) | 935.8K | ★ 3.8M |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 7.16 | N/A |
| Revenue | ★ $2,443,066,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $35.64 |
| Revenue Next Year | N/A | $34.12 |
| P/E Ratio | $6.86 | ★ N/A |
| Revenue Growth | ★ 30.99 | N/A |
| 52 Week Low | $11.86 | $3.50 |
| 52 Week High | $48.40 | $8.40 |
| Indicator | PARR | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 46.75 |
| Support Level | $33.67 | $5.47 |
| Resistance Level | $43.96 | $6.69 |
| Average True Range (ATR) | 1.95 | 0.35 |
| MACD | -0.30 | -0.10 |
| Stochastic Oscillator | 52.32 | 58.24 |
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.